ijms-logo

Journal Browser

Journal Browser

Expression of Signaling Genes in Cancer and Other Pathologies

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Genetics and Genomics".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 2024

Special Issue Editor


E-Mail Website
Guest Editor
Department of Molecular Carcinogenesis, Medical University of Łódź, 90-752 Łódź, Poland
Interests: gene expression; neurodegeneration; neurogenesis; cancer; WWOX gene
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Novel sequencing techniques now allow us to produce large amounts of transcriptomic data. The accessibility of these techniques is also greatly facilitated through public databases such as TCGA. Today, the scientific challenge is not to measure the gene expression level, but rather to interpret the biological meaning of it. The most reasonable approach seems to be to analyze entire functional genesets, since no protein functions alone and they all participate in well-orchestrated and incredibly complex cross-talk of cellular pathways.

I hereby invite you to contribute to the IJMS Special Issue entitled “Expression of Signaling Genes in Cancer and Other Pathologies”, which provides you with the opportunity to present your research to the scientific community. This Special Issue will present new findings on how alterations in gene expression and cell signaling drive the pathogenesis of cancer and other complex conditions.

We invite both high-quality research and review papers concerning broadly understood regulations of cellular signaling pathways.

I look forward to your submission.

Dr. Katarzyna Kośla
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • signaling pathways
  • gene expression
  • gene expression profile
  • cell signaling
  • cancer

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 1313 KiB  
Article
Breast Cancer Plasticity after Chemotherapy Highlights the Need for Re-Evaluation of Subtyping in Residual Cancer and Metastatic Tissues
by Irena Barbara Padzińska-Pruszyńska, Muhammad Waqas Akbar, Murat Isbilen, Emilia Górka, Baris Kucukkaraduman, Seçil Demirkol Canlı, Ege Dedeoğlu, Shila Azizolli, Isli Cela, Abbas Guven Akcay, Hasim Hakanoglu, Lubomir Bodnar, Szczepan Cierniak, Zygmunt Kozielec, Jacek Jerzy Pruszyński, Martyna Bittel, Ali Osmay Gure, Magdalena Król and Bartłomiej Taciak
Int. J. Mol. Sci. 2024, 25(11), 6054; https://doi.org/10.3390/ijms25116054 - 31 May 2024
Viewed by 223
Abstract
This research paper presents a novel approach to identifying biomarkers that can be used to prognosticate patients with triple-negative breast cancer (TNBC) eligible for neoadjuvant therapy. The study utilized survival and RNA sequencing data from a cohort of TNBC patients and identified 276 [...] Read more.
This research paper presents a novel approach to identifying biomarkers that can be used to prognosticate patients with triple-negative breast cancer (TNBC) eligible for neoadjuvant therapy. The study utilized survival and RNA sequencing data from a cohort of TNBC patients and identified 276 genes whose expression was related to survival in such patients. The gene expression data were then used to classify patients into two major groups based on the presence or absence of Wingless/Integrated-pathway (Wnt-pathway) and mesenchymal (Mes) markers (Wnt/Mes). Patients with a low expression of Wnt/Mes-related genes had a favorable outcome, with no deaths observed during follow-up, while patients with a high expression of Wnt/Mes genes had a higher mortality rate of 50% within 19 months. The identified gene list could be validated and potentially used to shape treatment options for TNBC patients eligible for neoadjuvant therapy providing valuable insights into the development of more effective treatments for TNBC. Our data also showed significant variation in gene expression profiles before and after chemotherapy, with most tumors switching to a more mesenchymal/stem cell-like profile. To verify this observation, we performed an in silico analysis to classify breast cancer tumors in Prediction Analysis of Microarray 50 (PAM50) molecular classes before treatment and after treatment using gene expression data. Our findings demonstrate that following drug intervention and metastasis, certain tumors undergo a transition to alternative subtypes, resulting in diminished therapeutic efficacy. This underscores the necessity for reevaluation of patients who have experienced relapse or metastasis post-chemotherapy, with a focus on molecular subtyping. Tailoring treatment strategies based on these refined subtypes is imperative to optimize therapeutic outcomes for affected individuals. Full article
(This article belongs to the Special Issue Expression of Signaling Genes in Cancer and Other Pathologies)
Show Figures

Figure 1

18 pages, 7119 KiB  
Article
Revealing the Role of Alternariol in the Local Steroidogenesis in Human Prostate Normal and Cancer Cells
by Kinga Anna Urbanek, Karolina Kowalska, Dominika Ewa Habrowska-Górczyńska, Marta Justyna Kozieł, Kamila Domińska and Agnieszka Wanda Piastowska-Ciesielska
Int. J. Mol. Sci. 2023, 24(11), 9513; https://doi.org/10.3390/ijms24119513 - 30 May 2023
Cited by 3 | Viewed by 1345
Abstract
The mycotoxin alternariol (AOH) can be found in food products infected by Alternaria spp. and is considered an endocrine-disruptive mycotoxin. The main mechanism of AOH toxicity is associated with DNA damage and modulation of the inflammation process. Still, AOH is considered as one [...] Read more.
The mycotoxin alternariol (AOH) can be found in food products infected by Alternaria spp. and is considered an endocrine-disruptive mycotoxin. The main mechanism of AOH toxicity is associated with DNA damage and modulation of the inflammation process. Still, AOH is considered as one of the emerging mycotoxins. In this study, we have evaluated how AOH might affect the local steroidogenesis process in the prostate, in both normal and cancer cells. We have found that AOH itself modulates the cell cycle, inflammation, and apoptosis, rather than the steroidogenesis process in prostate cancer cells; however, in the presence of another steroidogenic agent, the influence on steroidogenesis is significant. Therefore, this is the first study to report the effect of AOH on local steroidogenesis in normal and prostate cancer cells. We postulate that AOH might modulate the release of the steroid hormones and expression of the key components by interfering with the steroidogenic pathway and might be considered a steroidogenesis-altering agent. Full article
(This article belongs to the Special Issue Expression of Signaling Genes in Cancer and Other Pathologies)
Show Figures

Figure 1

Back to TopTop